The U.S Food and Drugs Administration (FDA) issued “deficiencies preclude discussion” receipt relating to the company’s New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin in managing glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). The receipt pointed out inadequacies in the applications that would preclude further discussion on the labeling or post-marketing at this level.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today declared that the company will cease its commercial business and align its operation and expenditure to save cash as much as possible while building its clinical development portfolio. This change of focus is expected to help foster more focused R&D efforts at developing products that are most likely to generate value-enhancing clinical innovations for patients.
“Even though this decision was not easy, it represents our dedication to creating sound business decisions to create value across our portfolio and support our lead-to-succeed strategy,” said Mike Exton Ph.D., CEO & Director of Lexicon. ‘We have a very strong pipeline of research and development ideas in store and therefore we shall focus on such programs most of which can create a great impact.’ Focusing on often under-served therapeutic areas that allow Lexicon to be the first and only therapy of its type, considering this model, we are focused on the opportunity to deliver relevant innovations to patients’ lives while establishing Lexicon as a market-ready organization for continual growth in the future.
It is significant to explain that Lexicon will eliminate the commercial field team; reduce all other departments’ size; and end all INPEFA® and ZYNQUISTA promotional activities in the process of restructuring. This restructuring plan will lead to the reduction of around 60% of the company’s workforce by the end of December 31. However, while scaling back on the commercial part of the business during the same process, Lexicon will continue producing and providing INPEFA to patients and their prescribers. The company expects it will be able to realize the operating cost controls of around $ 100 million in the complete year of 2025, and an additional $ 40 million of cost savings announced earlier under the resource rebalancing plan.
Following this, Lexicon will remain focused on the extension of its clinical development programs for the following products: These programs include the Phase 2b PROGRESS trial of LX9211 for diabetic peripheral neuropathic pain (DPNP), for which top-line data are expected in the first quarter of 2025. The company is also conducting the definitive phase 3 patient study of sotagliflozin in hypertrophic cardiomyopathy (HCM), called the SONATA HCM trial, for which enrolment is ongoing. In addition, concerning LX 9851, Lexicon is moving forward with an investigational new drug (IND)-enabling studies of its new oral development drug candidate for obesity and related cardiometabolic diseases (CMDs). It will also evaluate other potential indications for LX9851 and LX9211 while remaining open to continuing collaborations to drive the development of its product portfolio.
It is a biopharmaceutical company whose function of developing and manufacturing medicines changes the lives of patients. It has a new genomics target discovery tool Genome5000™ that helped the company’s scientists to identify protein targets of high drug relevance for a variety of diseases. Lexicon pipeline currently has several drugs for clinical investigation (preclinical and clinical phases), including some for neuropathic pain, metabolism diseases, and other conditions. It remains committed to progressing its treatments to meet the unmet needs of patients.
However, recent problems are non-relevant to Lexicon’s dedication to pipeline and selected therapy areas alter valuable development and changes in patients’ lives. The company still believes in the kind of future that the organization and its research and development (R&D) projects hold for the healthcare sector.
Indeed, as the company continues its way of moving toward clinical development, it must face the challenges that the biopharmaceutical industry has set in front of the company: to obtain approvals, find necessary capital, and execute the outlined strategic plans properly. However, Lexicon believes that by focusing on its strongest programs, it can position itself for future success and growth.
Reference: Lexicon Pharmaceuticals. Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA. Published November 22, 2024. Accessed January 2, 2025. https://www.globenewswire.com/news-release/2024/11/22/2985894/0/en/Lexicon-to-Reposition-as-Clinical-Development-Focused-Company-Following-Regulatory-Update-From-FDA.html
